COVID-19-Induced Actemra Shortage Causes Headaches For CAR-T Centers
Some Hematologists Report Having Problems Scheduling Cell Therapy
While some cancer centers report sufficient stocks of the drug, they have already been turning to potential alternatives due to supply issues that could last for weeks or months.
You may also be interested in...
Tocilizumab Shortage Prompts US FDA To Loosen CAR-T REMS Requirements
CAR-T cell immunotherapies can be administered when only one dose of Roche's Actemra is available on-site for each patient, rather than two doses required under REMS for the immunotherapies. The change is one of the few pandemic-related REMS revisions that has been made public.
As Cilta-Cel’s Big Day Approaches, Legend Looks Beyond Myeloma
CEO Ying Huang talked about the biotech’s plans for CAR-T therapies after its J&J-partnered program.
Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast edition of Scrip's Five Must-Know Things: US industry warns over pricing; a setback for another gene therapy; a Phase II disappointment for Novartis; Actemra shortages cause CAR-T worries; and Sweden's Sobi set to go private.